DuoBody®-PD-L1x4-1BB, KEYTRUDA 25 mg/mL concentrate for solution for infusion clinical trials

A Phase 2 Exploratory, Multicenter, Open-Label Trial to Determine the Safety and Preliminary Clinical Activity of GEN1046 in Combination With Anticancer Agents in Subjects With Advanced Endometrial Cancer

This study is looking into a new treatment for advanced endometrial cancer. It combines a new drug, called DuoBody®-PD-L1x4-1BB, with an existing cancer medicine, KEYTRUDA. Doctors want to see if this combination is safe and if it can shrink tumours.